



INTRODUCTION

Alzheimer's disease is a chronic neurodegenerative condition that impairs cognitive function and causes memory loss. Almost six million Americans suffer from Alzheimer's disease. There is no known cure. Key features of Alzheimer's disease (AD) are the accumulation of a protein called Amyloid-beta (A β) which eventually leads to large extracellular deposits called plaques. A second key feature of AD is the accumulation of Tau which eventually leads to large extracellular Tau tangles. Previous research found that induction of 40 Hz brain rhythms with various 40 Hz stimulation protocols leads to clearance of amyloid and tau (Iacrano, 2016) and improved cognition in mice modeling A β and Tau accumulation features of AD (Martorell, 2019) and more recently promising results have also been reported in human clinical trials (Chan, 2021). However, little is known about the details of such stimulation protocols, such as which features of 40Hz stimulation parameters are critical for inducing clearance of amyloid and tau, and which brain regions benefit from various stimulation protocols (and which may not). Therefore, as a first step, we hypothesize that 40 Hz light flickering (visual only protocol) can reduce Tau and A β aggregation in the parietal cortex of 3XTG-AD mice which have an intracellular accumulation of A β and tau (Stimmell et al., 2018). We also set out to confirm previous reports of clearance in the hippocampus and visual cortex using a visual-only protocol, but extended to a different mouse model and extended to conformationspecific markers of amyloid accumulation, targeting $A\beta$ conformations that are thought to be more pathological



Figure 1: Brain tissue being organized for mounting and imaging after histology

- Iaccarino HF, Singer AC, Martorell AJ, Rudenko A, Gao F, Gillingham TZ, Mathys H, Seo J, Kritskiy O, Abdurrob F, Adaikkan C, Canter RG, Rueda R, Brown EN, Boyden ES, Tsai LH. Gamma frequency entrainment attenuates amyloid load and modifies microglia. Nature. 2016 Dec 7;540(7632):230-235. DOI: 10.1038/nature20587. Erratum in: Nature. 2018 Oct;562(7725):E1. PMID: 27929004; PMCID: PMC5656389. - Stimmell AC, Xu Z, Moseley SC, et al. Tau Pathology Profile Across a Parietal-Hippocampal Brain Network Is Associated With Spatial Reorientation Learning and Memory Performance in the 3xTg-AD Mouse. Frontiers in Aging. 2021 May; 2. DOI: 10.3389/fragi.2021.655015. PMID: 34746919; PMCID: PMC8570590.

- Anthony J. Martorell, Abigail L. Paulson, Ho-Jun Suk, Fatema Abdurrob, Gabrielle T. Drummond, Webster Guan, Jennie Z. Young, David Nam-Woo Kim, Oleg Kritskiy, Scarlett J. Barker, Vamsi Mangena, Stephanie M. Prince, Emery N. Brown, Kwanghun Chung, Edward S. Boyden, Annabelle C. Singer, Li-Huei Tsai, Multi-sensory Gamma Stimulation Ameliorates Alzheimer's-Associated Pathology and Improves Cognition, Cell, Volume 177, Issue 2, 2019, Pages 256-271.e22, ISSN 0092-8674, - Chan, Diane and Suk, Ho-Jun and Jackson, Brennan L. and Milman, Noah Pollak and Stearns, Colton and Beach, Sara D. and Blanchard, Joel and Stearns, Colton and Boes, Aaron and Uitermarkt, Brandt and Gander, Phillip and Howard III, Matthew and Sternberg, Eliezer J. and Nieto-Castanon, Alfonso and Brown, Emery and Boyden, Edward S. and Dickerson, Bradford and Tsai, Li-Huei, Gamma Frequency Sensory Stimulation in Probable Mild Alzheimer's Dementia Patients: Results of a Preliminary Clinical Trial. Available at SSRN: <u>https://ssrn.com/abstract=3846540</u> or <u>http://dx.doi.org/10.2139/ssrn.3846540</u>

40 Hz light flickering as a possible treatment for Alzheimer's disease Anisa Shashaty, Danielle Cushing, Aaron Wilber

FSU Program in Neuroscience




Figure 3: 6e10 results graph

METHODS

- In this experiment, we used 6-month-old 3XTG-AD mice. These mice are genetically modified to accumulate amyloid-beta and Tau proteins

- The mice were split into a control group and an experimental group. The experimental group received 40Hz light stimulation for 1h in an otherwise dark box once a day for seven days while control mice remained in the home cage. - After the week of treatment, the mice were euthanized, and the brains were removed and sectioned (40μ slice thickness). - Antibodies (M22, M78, 6e10) were used to stain and identify specific amyloid-beta segments and conformations, and antibody AT8 for

a phosphorylated form of tau (pTau).

- We looked at three different regions of the brain: the parietal cortex (PC), the hippocampus (divided into ventral and dorsal subregions CA1v and CA1d), and the primary visual cortex (V1)


- Sections were stained for a neuronal marker (NeuN) visualized with a red flurophor, cell bodies of all cells visualized with a blue flurophor, and one marker of

pathology (e.g., M78)visualized with a green flurophor. - The density of neuronal cells positive for each marker of pathology will be compared between the two groups.

REFERENCES

Figure 4: M78 results graph

To find the results of this study we used ImageJ to manually count the neurons (labeled with the neuronal marker NeuN) that colocalized with a maker of Alzheimer's pathology. Using the ANOVA (analysis of variance) test, we examined the density of the pathology positive neurons in the experimental group (light treatment) compared to the control group (no treatment) for each brain region (parietal cortex, hippocampus, and visual cortex). This shows us how pathology varies as a function of each factor. Using a non-specific marker of A β , (6e10) we found a significant reduction in 6e10 positive neuron density in the PC and V1, but not the CA1v or CA1d. Next using a conformation antibody for a more pathological conformation of $A\beta$, the M78 stain, we again found a reduction in A β density within the treatment group in all brain regions assessed, particularly in the parietal cortex; however, surprisingly, the reduction was not large enough to be statistically significant.



DISCUSSION

This research is important because it could lead to improvements in a promising new treatment for Alzheimer's disease. Our research could help guide the human trials and future clinical trials. If light stimulation at 40Hz decreases pathology in mouse brains but only for the nonspecific A β 1-16 6e10 staining and not for a pathological confirmation of A β , then this is important new information that has implications for the effectiveness of this specific treatment in humans. A direction we could take our research in the future is changing the timeframe (or other parameters) of lightbox stimulation and seeing if that alters the pattern of the results. Finally, future work can compare light only stimulation to multisensory (light and sound) stimulation to see if these different approaches are more effective at reducing M78 positive cell densities.



RESULTS

Figure 2: Scanned section with cells (blue) and neurons (red) some of which are positive for M78 (green)